Turning to Probiotic Lactobacillus acidophilus for lowering cholesterol, and triglycerides levels and for promoting weight loss: Repurposing the Probiotic Lactobacillus acidophilus  into a cholesterol-lowering agent that inhibits Non-alcoholic fatty liver disease (NAFLD): Probiotic Lactobacillus acidophilus decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD, via up-regulation of its target gene, 21/September/2018, 5.17 pm

A derivative of Estrone comes to the rescue of anxiety and depression: Hydroxyestrone (16αOHE), a derivative of weak female reproductive steroid hormone Estrone, decreases PHF8 levels, increases the expression of serotonin receptors Htr1a and Htr2a, and promotes resistance to stress-induced -anxiety and -depression, via down-regulation of its target gene, 21/September/2018, 4.56 am
September 21, 2018
A probiotic way to lengthen lifespan: Probiotic Lactobacillus Previs increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 21/September/2018, 5.45 pm
September 21, 2018
Show all

The significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.


Research findings to Therapeutic opportunity:

This study suggests, first the first time, a Probiotic Lactobacillus acidophilus-based therapy for lowering cholesterol and triglyceride levels and to treat Non-alcoholic fatty liver disease (NAFLD). Probiotic Lactobacillus acidophilus has been shown to protect against irritable bowel syndrome. However, the mechanism of action remains largely unknown.

Probiotic Lactobacillus acidophilus, by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol, and total cholesterol levels; (2) attenuate lipid deposition in the liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, Probiotic Lactobacillus acidophilus, either alone or in combination with other drugs, may be used to treat NAFLD.

Figure 1. Mechanistic insights into how  Probiotic Lactobacillus acidophilus decreases the expression of HMGCR, lowers cholesterol levels, decreases triglyceride levels, and NAFLD.

Figure 2. Probiotic Lactobacillus acidophilus functions as a cholesterol-lowering agent. Probiotic Lactobacillus acidophilus lowers cholesterol and triglyceride levels and attenuates NAFLD through down-regulation of HMGCR

[easy_payment currency=”USD”]

 

 

 

 

 

 

 

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Probiotic Lactobacillus acidophilus decrease the expression of HMGCR and prevent NAFLD?

Amount: $750#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Turning to Probiotic Lactobacillus acidophilus for lowering cholesterol, and triglycerides levels and for promoting weight loss: Repurposing the Probiotic Lactobacillus acidophilus  into a cholesterol-lowering agent that inhibits Non-alcoholic fatty liver disease (NAFLD): Probiotic Lactobacillus acidophilus decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD, via up-regulation of its target gene, 21/September/2018, 5.17 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.